173 related articles for article (PubMed ID: 30453386)
21. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain SM; Whaley FS; Gerber MC; Weisberg S; York M; Spicer D; Jones SE; Wadler S; Desai A; Vogel C; Speyer J; Mittelman A; Reddy S; Pendergrass K; Velez-Garcia E; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1318-32. PubMed ID: 9193323
[TBL] [Abstract][Full Text] [Related]
22. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.
Mamas MA; Sperrin M; Watson MC; Coutts A; Wilde K; Burton C; Kadam UT; Kwok CS; Clark AB; Murchie P; Buchan I; Hannaford PC; Myint PK
Eur J Heart Fail; 2017 Sep; 19(9):1095-1104. PubMed ID: 28470962
[TBL] [Abstract][Full Text] [Related]
23. Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study.
Lee YB; Han K; Kim B; Lee SE; Jun JE; Ahn J; Kim G; Jin SM; Kim JH
Cardiovasc Diabetol; 2019 Nov; 18(1):157. PubMed ID: 31733656
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
[TBL] [Abstract][Full Text] [Related]
26. TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
Liang S; Xinyong C; Hongmin Z; Jing W; Lang H; Ping Z
Toxicol Lett; 2018 Oct; 295():205-211. PubMed ID: 29959987
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
28. Hypertensive disorders of pregnancy and future heart failure risk: A nationwide population-based retrospective cohort study.
Chen SN; Cheng CC; Tsui KH; Tang PL; Chern CU; Huang WC; Lin LT
Pregnancy Hypertens; 2018 Jul; 13():110-115. PubMed ID: 30177036
[TBL] [Abstract][Full Text] [Related]
29. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women: A Nationwide Cohort Study.
Chien HC; Kao Yang YH; Bai JP
JAMA Oncol; 2016 Oct; 2(10):1317-1325. PubMed ID: 27310478
[TBL] [Abstract][Full Text] [Related]
31. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
32. Prediction of new-onset refractory congestive heart failure using gated myocardial perfusion SPECT imaging in patients with known or suspected coronary artery disease subanalysis of the J-ACCESS database.
Nakata T; Hashimoto A; Wakabayashi T; Kusuoka H; Nishimura T
JACC Cardiovasc Imaging; 2009 Dec; 2(12):1393-400. PubMed ID: 20083074
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
Choi JY; Cho EY; Choi YJ; Lee JH; Jung SP; Cho KR; Kim CY; Kim YH; Park KH
Breast Cancer Res Treat; 2018 Aug; 171(1):181-188. PubMed ID: 29737474
[TBL] [Abstract][Full Text] [Related]
34. Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease.
Chen HF; Ho CA; Li CY
Diabetes Obes Metab; 2019 Jan; 21(1):112-119. PubMed ID: 30091215
[TBL] [Abstract][Full Text] [Related]
35. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
[TBL] [Abstract][Full Text] [Related]
36. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
[TBL] [Abstract][Full Text] [Related]
37. Weight change and the incidence of heart failure in the Korean population: data from the National Health Insurance Health checkup 2005-2015.
Kim YH; Han KD; Jung JH; Yoo SJ; Lee SS; Lee WY; Park HS; Kim SM;
Eur J Prev Cardiol; 2022 Jan; 28(16):1767-1773. PubMed ID: 33823535
[TBL] [Abstract][Full Text] [Related]
38. The limited prognostic role of echocardiograms in short-term follow-up after acute decompensated heart failure: An analysis of the Korean Heart Failure (KorHF) Registry.
Kim SH; Kim HJ; Han S; Yoo BS; Choi DJ; Kim JJ; Jeon ES; Cho MC; Chae SC; Ryu KH
PLoS One; 2017; 12(12):e0188938. PubMed ID: 29261675
[TBL] [Abstract][Full Text] [Related]
39. Moderate to Severe Renal Insufficiency Is Associated With High Mortality After Hip and Knee Replacement.
Jämsä P; Jämsen E; Huhtala H; Eskelinen A; Oksala N
Clin Orthop Relat Res; 2018 Jun; 476(6):1284-1292. PubMed ID: 29601379
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
